Which has preferable valuation and earnings, QGEN or BNTX?

Qiagen has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qiagen $2.09B 3.62 $424.88M $1.91 19.21 BioNTech $3.25B 6.86 -$1.29B -$5.88 N/A

Is QGEN or BNTX more profitable?

Qiagen has a net margin of 19.16% compared to BioNTech's net margin of -44.39%. Qiagen's return on equity of 14.40% beat BioNTech's return on equity. Company Net Margins Return on Equity Return on Assets Qiagen 19.16% 14.40% 8.40% BioNTech -44.39% -5.30% -4.62%

Does the media prefer QGEN or BNTX?

In the previous week, BioNTech had 3 more articles in the media than Qiagen. MarketBeat recorded 8 mentions for BioNTech and 5 mentions for Qiagen. Qiagen's average media sentiment score of 0.47 beat BioNTech's score of 0.46 indicating that Qiagen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioNTech 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, INSM or QGEN?

Qiagen has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 33.68 -$1.28B -$5.75 N/A Qiagen $2.09B 3.62 $424.88M $1.91 19.21

Is INSM or QGEN more profitable?

Qiagen has a net margin of 19.16% compared to Insmed's net margin of -144.44%. Qiagen's return on equity of 14.40% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -144.44% -130.11% -51.57% Qiagen 19.16% 14.40% 8.40%

Does the media refer more to INSM or QGEN?

In the previous week, Insmed had 16 more articles in the media than Qiagen. MarketBeat recorded 21 mentions for Insmed and 5 mentions for Qiagen. Insmed's average media sentiment score of 0.88 beat Qiagen's score of 0.47 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 14 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, ROIV or QGEN?

Qiagen has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Roivant Sciences $8.26M 2,488.71 -$299.77M -$0.60 N/A Qiagen $2.09B 3.62 $424.88M $1.91 19.21

Is ROIV or QGEN more profitable?

Qiagen has a net margin of 19.16% compared to Roivant Sciences' net margin of -3,629.19%. Qiagen's return on equity of 14.40% beat Roivant Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Roivant Sciences -3,629.19% -20.54% -19.43% Qiagen 19.16% 14.40% 8.40%

Does the media refer more to ROIV or QGEN?

In the previous week, Roivant Sciences had 5 more articles in the media than Qiagen. MarketBeat recorded 10 mentions for Roivant Sciences and 5 mentions for Qiagen. Roivant Sciences' average media sentiment score of 1.10 beat Qiagen's score of 0.47 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, QGEN or VTRS?

Qiagen has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qiagen $2.09B 3.62 $424.88M $1.91 19.21 Viatris $14.30B 1.29 -$3.51B -$0.26 N/A

Is QGEN or VTRS more profitable?

Qiagen has a net margin of 19.16% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Qiagen's return on equity. Company Net Margins Return on Equity Return on Assets Qiagen 19.16% 14.40% 8.40% Viatris -2.04% 19.04% 7.62%

Does the media refer more to QGEN or VTRS?

In the previous week, Qiagen had 2 more articles in the media than Viatris. MarketBeat recorded 5 mentions for Qiagen and 3 mentions for Viatris. Viatris' average media sentiment score of 0.54 beat Qiagen's score of 0.47 indicating that Viatris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viatris 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, MRNA or QGEN?

Qiagen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moderna $1.94B 9.68 -$2.82B -$8.15 N/A Qiagen $2.09B 3.62 $424.88M $1.91 19.21

Is MRNA or QGEN more profitable?

Qiagen has a net margin of 19.16% compared to Moderna's net margin of -143.55%. Qiagen's return on equity of 14.40% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -143.55% -26.64% -19.32% Qiagen 19.16% 14.40% 8.40%

Does the media favor MRNA or QGEN?

In the previous week, Moderna had 26 more articles in the media than Qiagen. MarketBeat recorded 31 mentions for Moderna and 5 mentions for Qiagen. Moderna's average media sentiment score of 0.48 beat Qiagen's score of 0.47 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 13 Very Positive mention(s) 4 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 4 Very Negative mention(s) Neutral Qiagen 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Qiagen (QGEN) Competitors

$36.68 -0.88 (-2.33%)

Closing price 06/5/2026 03:59 PM Eastern

Extended Trading

$36.70 +0.01 (+0.03%)

As of 06/5/2026 05:55 PM Eastern

Compare

QGEN vs. BNTX, INSM, ROIV, VTRS, and MRNA

Should you buy Qiagen stock or one of its competitors? MarketBeat compares Qiagen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Qiagen include BioNTech (BNTX), Insmed (INSM), Roivant Sciences (ROIV), Viatris (VTRS), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.

How does Qiagen compare to BioNTech?

Qiagen (NYSE:QGEN) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Qiagen has a net margin of 19.16% compared to BioNTech's net margin of -44.39%. Qiagen's return on equity of 14.40% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
BioNTech	-44.39%	-5.30%	-4.62%

In the previous week, BioNTech had 3 more articles in the media than Qiagen. MarketBeat recorded 8 mentions for BioNTech and 5 mentions for Qiagen. Qiagen's average media sentiment score of 0.47 beat BioNTech's score of 0.46 indicating that Qiagen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNTech	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Qiagen presently has a consensus price target of $44.98, indicating a potential upside of 22.61%. BioNTech has a consensus price target of $129.56, indicating a potential upside of 47.10%. Given BioNTech's stronger consensus rating and higher probable upside, analysts clearly believe BioNTech is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

Qiagen has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market.

Qiagen has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.62	$424.88M	$1.91	19.21
BioNTech	$3.25B	6.86	-$1.29B	-$5.88	N/A

70.0% of Qiagen shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Qiagen and BioNTech tied by winning 8 of the 16 factors compared between the two stocks.

How does Qiagen compare to Insmed?

Insmed (NASDAQ:INSM) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

70.0% of Qiagen shares are owned by institutional investors. 2.1% of Insmed shares are owned by company insiders. Comparatively, 9.0% of Qiagen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Insmed has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. Comparatively, Qiagen has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

Qiagen has a net margin of 19.16% compared to Insmed's net margin of -144.44%. Qiagen's return on equity of 14.40% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Qiagen	19.16%	14.40%	8.40%

Qiagen has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	33.68	-$1.28B	-$5.75	N/A
Qiagen	$2.09B	3.62	$424.88M	$1.91	19.21

Insmed currently has a consensus price target of $210.50, suggesting a potential upside of 123.41%. Qiagen has a consensus price target of $44.98, suggesting a potential upside of 22.61%. Given Insmed's stronger consensus rating and higher probable upside, equities research analysts clearly believe Insmed is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Qiagen	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42

In the previous week, Insmed had 16 more articles in the media than Qiagen. MarketBeat recorded 21 mentions for Insmed and 5 mentions for Qiagen. Insmed's average media sentiment score of 0.88 beat Qiagen's score of 0.47 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	14 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Qiagen beats Insmed on 9 of the 16 factors compared between the two stocks.

How does Qiagen compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

In the previous week, Roivant Sciences had 5 more articles in the media than Qiagen. MarketBeat recorded 10 mentions for Roivant Sciences and 5 mentions for Qiagen. Roivant Sciences' average media sentiment score of 1.10 beat Qiagen's score of 0.47 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Roivant Sciences currently has a consensus target price of $33.59, suggesting a potential upside of 17.53%. Qiagen has a consensus target price of $44.98, suggesting a potential upside of 22.61%. Given Qiagen's higher possible upside, analysts clearly believe Qiagen is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Qiagen	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by insiders. Comparatively, 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Roivant Sciences has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, Qiagen has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

Qiagen has a net margin of 19.16% compared to Roivant Sciences' net margin of -3,629.19%. Qiagen's return on equity of 14.40% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Qiagen	19.16%	14.40%	8.40%

Qiagen has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,488.71	-$299.77M	-$0.60	N/A
Qiagen	$2.09B	3.62	$424.88M	$1.91	19.21

Summary

Qiagen beats Roivant Sciences on 9 of the 16 factors compared between the two stocks.

How does Qiagen compare to Viatris?

Qiagen (NYSE:QGEN) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

Qiagen has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market. Comparatively, Viatris has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

Qiagen pays an annual dividend of $0.26 per share and has a dividend yield of 0.7%. Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 3.0%. Qiagen pays out 13.6% of its earnings in the form of a dividend. Viatris pays out -184.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Viatris is clearly the better dividend stock, given its higher yield and lower payout ratio.

Qiagen currently has a consensus target price of $44.98, indicating a potential upside of 22.61%. Viatris has a consensus target price of $17.50, indicating a potential upside of 10.20%. Given Qiagen's higher probable upside, analysts plainly believe Qiagen is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Qiagen has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.62	$424.88M	$1.91	19.21
Viatris	$14.30B	1.29	-$3.51B	-$0.26	N/A

Qiagen has a net margin of 19.16% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Qiagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Viatris	-2.04%	19.04%	7.62%

70.0% of Qiagen shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 0.3% of Viatris shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Qiagen had 2 more articles in the media than Viatris. MarketBeat recorded 5 mentions for Qiagen and 3 mentions for Viatris. Viatris' average media sentiment score of 0.54 beat Qiagen's score of 0.47 indicating that Viatris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Qiagen beats Viatris on 10 of the 18 factors compared between the two stocks.

How does Qiagen compare to Moderna?

Moderna (NASDAQ:MRNA) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Moderna has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, Qiagen has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market.

Moderna presently has a consensus price target of $35.73, indicating a potential downside of 24.68%. Qiagen has a consensus price target of $44.98, indicating a potential upside of 22.61%. Given Qiagen's stronger consensus rating and higher probable upside, analysts plainly believe Qiagen is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83
Qiagen	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42

Qiagen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	9.68	-$2.82B	-$8.15	N/A
Qiagen	$2.09B	3.62	$424.88M	$1.91	19.21

Qiagen has a net margin of 19.16% compared to Moderna's net margin of -143.55%. Qiagen's return on equity of 14.40% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Qiagen	19.16%	14.40%	8.40%

75.3% of Moderna shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Comparatively, 9.0% of Qiagen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Moderna had 26 more articles in the media than Qiagen. MarketBeat recorded 31 mentions for Moderna and 5 mentions for Qiagen. Moderna's average media sentiment score of 0.48 beat Qiagen's score of 0.47 indicating that Moderna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	13 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	4 Very Negative mention(s)	Neutral
Qiagen	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Qiagen beats Moderna on 10 of the 16 factors compared between the two stocks.

Get Qiagen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QGEN vs. The Competition

Export

Metric	Qiagen	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$7.56B	$3.35B	$6.64B	$23.35B
Dividend Yield	0.72%	2.33%	2.68%	4.08%
P/E Ratio	15.07	19.02	23.84	30.26
Price / Sales	3.62	308.79	577.54	13.22
Price / Cash	10.77	116.12	42.42	24.41
Price / Book	2.05	6.51	9.73	4.63
Net Income	$424.88M	$24.19M	$3.57B	$1.07B
7 Day Performance	0.18%	-6.96%	-1.26%	-1.66%
1 Month Performance	6.47%	-4.27%	0.82%	-1.68%
1 Year Performance	-23.37%	36.81%	24.09%	21.33%

Qiagen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QGEN Qiagen	4.2641 of 5 stars	$36.69 -2.3%	$44.98 +22.6%	-23.6%	$7.56B	$2.09B	15.07	5,654
BNTX BioNTech	4.0048 of 5 stars	$91.70 -4.4%	$129.56 +41.3%	-20.0%	$24.26B	$3.25B	N/A	7,807	Analyst Forecast
INSM Insmed	3.7479 of 5 stars	$106.03 -0.8%	$210.95 +99.0%	+29.5%	$23.17B	$606.42M	N/A	1,664	Analyst Forecast Insider Trade
ROIV Roivant Sciences	3.1446 of 5 stars	$29.09 -3.0%	$33.59 +15.5%	+155.2%	$21.57B	$8.26M	N/A	860	News Coverage Positive News
VTRS Viatris	3.4802 of 5 stars	$15.81 -2.8%	$16.43 +3.9%	+87.7%	$18.94B	$14.30B	N/A	30,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:QGEN) was last updated on 6/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Qiagen (QGEN) Competitors